(Updated - December 22, 2022 6:03 AM EST)

Oppenheimer analyst Matthew Biegler downgraded Celularity (NASDAQ: CELU) from Outperform to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE